Overview
HBOT for PTSD has been studied primarily in military veteran populations with comorbid TBI. Results suggest meaningful symptom reduction in patients who have the TBI/PTSD overlap, though isolating HBOT's effect on pure PTSD without TBI remains difficult. The Harch group has published multiple small trials.
PTSD and TBI frequently co-occur in military veterans — the combination has been termed "polytrauma" in VA literature. Both conditions share overlapping symptom profiles (sleep disturbance, cognitive dysfunction, mood dysregulation) and may share neurobiological features including altered connectivity and hypoperfusion in specific brain regions.
HBOT research for PTSD has largely emerged from veteran populations with mixed TBI/PTSD presentations. Studies by Paul Harch (LSU) and others have reported symptom improvements across both PTSD and TBI measures, though isolating the HBOT effect on PTSD specifically — vs the effect mediated through TBI improvement — remains methodologically difficult.
Current consensus: HBOT is not an established treatment for isolated PTSD. For veterans with the TBI/PTSD overlap, HBOT research continues to show signal. Standard-of-care PTSD treatment (trauma-focused psychotherapy, SSRI/SNRI pharmacotherapy) remains the first-line approach.
How HBOT Works for This Condition
Hypothesised mechanisms include reduction of neuroinflammation (implicated in both TBI and PTSD), improved cerebral perfusion in previously hypoperfused brain regions, and effects on hippocampal volume and function. The exact mechanism in PTSD specifically — as distinct from the TBI effect — is unclear.
GRADE Evidence Rating
Harch 2017 positive signal; Cifu 2014 BRIMS trial negative. Sham-chamber design remains a methodological issue.
| GRADE Domain | Assessment |
|---|---|
| Risk of bias | Moderate |
| Consistency | Inconsistent |
| Directness | Direct |
| Precision | Imprecise |
GRADE methodology: Grading of Recommendations Assessment, Development and Evaluation. See GRADE Working Group.
Clinical Protocol
| Typical protocol | 40 sessions at 1.5–2.0 ATA |
|---|---|
| Evidence level | Early-phase trials — Limited evidence |
| FDA status | Not FDA-approved |
Protocols vary. Harch-group trials have used both 1.5 ATA and 2.0 ATA with 40-session courses. The 2.0 ATA Efrati-aligned protocols are increasingly favoured for the overlap TBI/PTSD population.
Evidence Base
HBOT for PTSD specifically is Tier 3 (investigational). The data are limited to small, often open-label trials. Larger RCTs in veteran populations are either underway or anticipated. Standard-of-care PTSD treatment remains the primary recommendation.
Patient Perspective
Veterans and civilians with PTSD considering HBOT typically have either overlap TBI/PTSD or have not responded fully to standard PTSD treatment. HBOT is an adjunct to — not a replacement for — trauma-focused psychotherapy and medication. Patients should maintain their existing mental health treatment during an HBOT course.
Cautions & Considerations
- HBOT does not replace trauma-focused psychotherapy or SSRIs/SNRIs.
- Evidence base is limited; much data comes from TBI/PTSD overlap populations.
- Not FDA-approved; usually cash-pay or specific state programmes for veterans.
- Standard HBOT contraindications apply.
Key Research & References
- Harch et al. 2017 (veterans)
- Mozayeni et al. 2019
- Various DoD trials
Indexed Studies for This Condition
Linked entries in the HBOT Studies Database.
Frequently Asked Questions
Is HBOT a cure for PTSD?
No. HBOT is studied as an adjunct that may support recovery, particularly in veterans with overlapping TBI. Standard-of-care PTSD treatment (psychotherapy, medications) remains the first-line approach.
Should I stop my PTSD medications during HBOT?
No. Patients should maintain their existing PTSD medication and psychotherapy regimen during an HBOT course. Medication adjustments should be made with the prescribing physician, not stopped unilaterally.
Does the VA cover HBOT for PTSD?
Not as a national benefit. State-level programmes and specific VA pilot studies have provided access for selected veterans. Most PTSD HBOT remains out-of-pocket.
Research disclaimer: This article summarises published research for educational purposes only. Nothing here is medical advice. HBOT is a prescription medical treatment that must be administered under physician supervision in appropriately certified chambers. Discuss any treatment decisions with a qualified clinician.